


Oncology
2024-04-10

The interaction between PD-1 and PD-L1 promotes tumor immune evasion, but immune checkpoint inhibitors can reinvigorate the immune system. However, most patients don't respond well to anti-PD-1/PD-L1 therapy, leading to acquired resistance. Establishing reliable preclinical resistance models is vital for understanding resistance mechanisms and developing new treatments.
More infomation about blogs

Let us know which event you're attending and we'd be happy to connect with you.
This website will store cookies on your computer. These cookies are used to collect information about how you interact with this website and enable us to remember you. We use this information to improve and customize your browsing experience, as well as to analyze and collect relevant data and metrics about visitors on this website and other platforms. For more information about the cookies we use, please refer to our privacy policy
If you decline, your information will not be tracked when visiting this website. A cookie will be used in your browser to remember your preference settings that you have not accepted.
